FBLG Q2 2023 Earnings — FibroBiologics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

FBLGFibroBiologics, Inc. Common Stock

$17M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.07

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$448,000

Balance Sheet

Total Assets

$14M

Total Liabilities

$2M

Stockholders' Equity

$11M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$911,000	-129.7%
Net Income	-$2M	-$1M	-112.3%